Compare YieldMax COIN Option Income Strategy ETF (CONY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs BIO-TECHNE Corp — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18, while BIO-TECHNE Corp trades at $72.06 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while YieldMax COIN Option Income Strategy ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | TECH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $72.29 |
52-Week Low | $17.80 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $18.54, up 4.16% today, with a bearish technical signal from moving averages but oversold RSI levels. The ETF shows no fundamental valuation ratios available, and recent news highlights significant shareholder losses despite high distribution yields. Weekly dividends are consistently announced, but underlying performance concerns persist.
Outlook remains cautious due to bearish technicals and negative media sentiment emphasizing value erosion. Risks include reliance on options income strategy and Coinbase volatility. Analyst coverage suggests skepticism, with no bullish catalysts evident near-term.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
